FCGR2A and myeloid sarcoma: Together these data add to the evidence suggesting an important role of BTK in FcGR-mediated brain inflammation [48] and support a mechanistic facet of potential remibrutinib efficacy in MS in addition to peripheral B cell and macrophage inhibition.